European Union & GT Biopharma

European Union: The European Union is a key market where Imlifidase is conditionally approved and where the PAES study was conducted, leading to the upcoming application for full marketing authorization.

GT Biopharma: GT Biopharma announced positive topline results from its European Post Authorization Efficacy Study for Imlifidase, fulfilling a key requirement for full marketing authorization and boosting its product's market potential.

European Union: The European Union>>> is a key region where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.

GT Biopharma: GT Biopharma>>> divested the European and MENA rights to Imlifidase for 115 million euros, allowing it to focus on other markets and receive significant payments.